Michael Reardon, ACC 2022: Insights from the Corevalve US Pivotal and SURTAVI trials: Five-year incidence, timing and predictors of hemodynamic valve deterioration of transcatheter and surgical aortic bioprostheses

Both the CoreValve US pivotal and SURTAVI trials investigated the five-year incidence, timing and predictors of haemodynamic valve deterioration of transcatheter aortic valve replacement (TAVR) surgery and surgical aortic bioprostheses in the treatment of severe, symptomatic aortic stenosis. Prof. Michael Reardon (Houston Methodist Hospital, Houston, TX) shares the insights and findings from these trials.

Questions:

1. Could you give us a brief overview of the evolution of transcatheter aortic valve replacement (TAVR) surgery and the unanswered questions regarding its use? (00:20)
2. What are the aims, design and findings of this substudy of the CoreValve U.S. Pivotal and SURTAVI trials looking at structural valve deterioration? (01:12)
3. What are the take-home messages from the data? (03:19)
4. What will be the focus of future research? (04:14)

Disclosures: Michael Reardon is a consultant for Abbott Medical, Boston Scientific, Gore Medical and Medtronic and discloses grant/research support from Abbott Medical, Boston Scientific, Gore Medical and Medtronic.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Filmed in coverage of the American College of Cardiology Annual Meeting 2022